الفهرس 
Osteosarcoma of the extremities at National Cancer Institute (Cairo University Egypt), treatment outcome and prognostic factors
AbstractOnly 14 pages are availabe for public view
 |  | from | 223 |  |  |
| | | from | 223 | | |
Abstract
Osteosarcoma accounting for less than %2.0 of malignant tumors and about 65 % of all bone cancers in individuals under the age of .%, although the overall survival have improved dramatically yet it remains a challenging disease especially in developing countries. Thirty one (13) of newly diagnosed osteosarcoma patients who presented to National Cancer Institute, Cairo University, Egypt were considered eligible in this retrospective study, aiming for identifying survival outcome and correlation of outcome with different risk factors. Available data of the included patients were collected such as; age, gender, primary tumor volume, and extent of the disease. The 1 years DFS was found to be 1.53 %. The 1 years OS was 3357%.Tumor volume, elevated alkaline phosphatase at presentation, positive surgical margin and delay of resuming chemotherapy more than 12 days post-surgery proved to be statistically significant and had their impact on survival. Other factors proved to be insignificant. Although HDMTX and cisplatin free regimen produce outcome comparable to other protocols using cisplatin and HDMTX-containing regimens and offers a good alternative for patients particularly those with intolerance to HDMTX and for institutions that cannot provide HDMTX pharmacokinetic monitoring in other countries, our study protocol does not seem reasonable for our patient population due to its poor outcome when compared to other studies